NeuroFields

NeuroFieldz is a company that has developed a revolutionary device called NeuroVEP, which combines a virtual reality headset with a smartphone and brain sensor to diagnose vision and related neurological problems. The device works by converting brain signals, known as Visual Evoked Potentials (VEP), into a map representing the parts of a user's visual field that may have decreased function.

NeuroVEP utilizes advanced technologies such as machine learning and artificial intelligence to analyze and isolate these brain signals. The headset is equipped with a sensor that monitors the brain signals produced by the user, while the smartphone provides visual stimuli to activate these signals. The device also plays podcasts to keep the user engaged during the process.

A key advantage of NeuroVEP is its objectivity. Unlike traditional vision tests where patients self-report their vision, NeuroVEP provides an objective assessment based on the user's brain signals. Additionally, the device is highly portable, unlike similar cart-based systems, making it easier to use in various clinical settings.

NeuroVEP has been tested with approximately 200 patients through partnerships with Tufts Medical Center, Boston Children's Hospital, and other clinics as of September 2023. The device has shown promising results, with clinicians reporting that it outperformed the current standard of care cart-based systems and worked flawlessly in testing over 150 patients with macular degeneration.

While NeuroVEP is still in the development phase and has not yet received regulatory approval for marketing or commercial use, the company envisions the technology being applied to diagnose various neuro-visual disorders, including glaucoma, multiple sclerosis, traumatic brain injury, visual field defects, macular degeneration, optical neuritis, cancer tumors, and amblyopia.

Key customers and partnerships

NeuroFieldz has formed partnerships with Tufts Medical Center, Boston Children's Hospital, and other clinics to test the NeuroVEP device as of September 2023. These partnerships have allowed the company to conduct clinical trials and gather feedback from patients and clinicians, which has been positive, with reports of the device outperforming current standards and being well-received by users.